Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: Outcomes in the Japanese subgroup of the VIEW 2 study

British Journal of Ophthalmology

Volumn 99, Issue 1, 2015, Pages 92-97

  Ogura, Yuichiro ^a   Terasaki, Hiroko ^b   Gomi, Fumi ^c   Yuzawa, Mitsuko ^d   Iida, Tomohiro ^e   Honda, Miki ^f   Nishijo, Koichi ^g   Sowade, Olaf ^h   Komori, Tetsushi ^g   Schmidt Erfurth, Ursula ⁱ   Simader, Christian ⁱ   Chong, Victor ^j  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d NIHON UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^g BAYER YAKUHIN LTD   (Japan)

^h BAYER PHARMA AG   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; VASCULOTROPIN ANTIBODY; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CONTROLLED STUDY; CORNEA EDEMA; CORNEA EROSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE EDEMA; EYE PAIN; EYELID EDEMA; FEMALE; FOREIGN BODY; HUMAN; HYPEREMIA; INCIDENCE; INJECTION SITE PAIN; INTRAOCULAR PRESSURE ABNORMALITY; JAPANESE (PEOPLE); LACRIMATION DISORDER; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA TEAR; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS FLOATERS; VITREOUS OPACITY; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DRUG EFFECTS; ETHNOLOGY; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; JAPAN; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84919385698     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305076     Document Type: Article

References (18)

1. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119: 2537-48.
2. Bird AC. The Bowman lecture. Towards an understanding of age-related macular disease. Eye (Lond) 2003;17: 457-66.
3. Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: The Funagata study. Ophthalmology 2008;115: 1376-81, 1381.
4. Oshima Y, Ishibashi T, Murata T, et al. Prevalence of age related maculopathy in a representative Japanese population: The Hisayama study. Br J Ophthalmol 2001;85: 1153-7.
5. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144: 15-22.
6. Mori K, Horie-Inoue K, Gehlbach PL, et al. Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. Ophthalmology 2010;117: 928-38.
7. Uyama M, Takahashi K, Ida N, et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. Br J Ophthalmol 2000;84: 1018-23.
8. Kawasaki R, Wang JJ, Amirul FM, et al. Is bilateral age-related macular degeneration less common in Asians than Caucasians? Ophthalmic Epidemiol 2011;18: 253-8.
9. Saito M, Iida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina 2012;32: 1250-9.
10. Matsumiya W, Honda S, Kusuhara S, et al. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): Comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up. BMC Ophthalmol 2013;13: 10.
11. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet 2012;379: 1728-38.
12. Hayashi H, Yamashiro K, Gotoh N, et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 2010;51: 5914-19.
13. Gotoh N, Nakanishi H, Hayashi H, et al. ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;147: 1037-41, 1041.
14. Suzuki M, Gomi F, Sawa M, et al. Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. Jpn J Ophthalmol 2010;54: 124-8.
15. Tano Y, Ohji M. EXTEND-I: Safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 2010;88: 309-16.
16. Tano Y, Ohji M. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol 2011;89: 208-17.
17. Basic principles on Global Clincal Trials. http://www pmda go jp/kijunsakusei/file/guideline/new-drug/GlobalClinicalTrials-en pdf.
18. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120: 122-9.